{"nctId":"NCT02487030","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","startDateStruct":{"date":"2015-09-07","type":"ACTUAL"},"conditions":["Hepatitis C Virus Infection"],"count":255,"armGroups":[{"label":"LDV/SOF 8 wk TN (Cohort 1, Group 1)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]},{"label":"LDV/SOF 12 wk TN (Cohort 1, Group 3)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]},{"label":"LDV/SOF+RBV 12 wk TE (Cohort 2)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]},{"label":"LDV/SOF 12 wk TE (Cohort 3, Group 1)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF"]},{"label":"LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)","type":"EXPERIMENTAL","interventionNames":["Drug: LDV/SOF","Drug: RBV"]}],"interventions":[{"name":"LDV/SOF","otherNames":["Harvoni®","GS-5885/GS-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Chronic HCV infection (≥ 6 months) documented by medical history or liver biopsy\n* HCV genotype 4 at screening\n* HCV treatment naive or prior participation in this study or study GS-US-334-0138 (Cohorts 1 and 2 only)\n* Cohort 3 only: HCV treatment-experienced (previously received therapy for HCV infection with an interferon (IFN)-containing regimen, with or without RBV and/or an HCV NS3/NS4A protease inhibitor (PI)\n* Body mass index (BMI) ≥ 18 kg/m\\^2\n* Screening laboratory values within defined thresholds\n* Use of effective protocol-approved contraception methods\n\nKey Exclusion Criteria:\n\n* History of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment or compliance with the protocol\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n* Pregnant or nursing females or male with pregnant female partner\n* Clinically-relevant drug or alcohol abuse within 12 months of screening\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.","paramType":"NUMBER","dispersionType":"99% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"97.7","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"94.4","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued LDV/SOF Drug Due to an Adverse Event (AE)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR24 were defined as HCV RNA \\< LLOQ 4 and 24 weeks after the last dose of study drug, respectively.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"95.2","spread":null},{"groupId":"OG002","value":"97.7","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"100.0","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"97.7","spread":null},{"groupId":"OG003","value":"97.6","spread":null},{"groupId":"OG004","value":"94.4","spread":null},{"groupId":"OG005","value":"100.0","spread":null},{"groupId":"OG006","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Overall Virologic Failure","description":"Virologic failure was defined as\n\n* On-treatment virologic failure\n\n  * confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ, while on treatment (ie, breakthrough),\n  * confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound),\n  * HCV RNA persistently ≥ LLOQ through 8 weeks of treatment (ie, nonresponse)\n* Relapse\n\n  * HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"9.5","spread":null},{"groupId":"OG002","value":"2.3","spread":null},{"groupId":"OG003","value":"0.0","spread":null},{"groupId":"OG004","value":"2.8","spread":null},{"groupId":"OG005","value":"0.0","spread":null},{"groupId":"OG006","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["Headache","Fatigue","Dyspepsia","Anaemia","Bronchitis"]}}}